T he central goals of breast cancer treatment are maximizing survival, reducing risk of recurrence, and preserving the normal appearance of the breast. Achieving these goals requires use of local therapies including surgery and radiation in combination with systemic chemotherapy and endocrine therapy. Discussion continues as to the optimum extent of each treatment and sequence of each modality relative to the others. 1 Increasingly, treatments and treatment sequences are individualized on the basis of the features of the individual patient and her tumor.
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For most breast cancer patients, the first intervention is surgery, followed by "adjuvant" systemic therapy. Use of systemic therapy before surgery was initially reserved for patients with inoperable and locally advanced tumors. This preoperative or "neoadjuvant" approach can reduce the size of tumor deposits at primary and nodal sites and can convert inoperable tumors into an operable state.
Systemic therapy has also been explored as the first treatment modality in patients with operable breast cancers. In theory, delivery of systemic therapy first might improve overall survival by eliminating occult metastatic tumor deposits earlier in the course of treatment. It was also hoped that administering chemotherapy first would allow adjustment of systemic therapy regimens based on the primary tumor response, making it possible to discontinue ineffective drugs and try alternative agents until an effective regimen was found.
Unfortunately, neither of these hopes has yet been realized. Survival was no better (but no worse) with preoperative versus postoperative chemotherapy in any of the prospective randomized trials. [2] [3] [4] Thus, although systemic therapy is clearly beneficial for overall and disease-free survival in breast cancer patients, the timing of systemic therapy relative to surgery is not important. It has also not been possible to tailor treatment regimens to primary tumor response, largely due to the lack of reliable early markers of tumor response.
Despite these negative results, use of preoperative chemotherapy in operable breast cancers has provided several useful therapeutic insights. Perhaps most important is the observation that approximately 80% of primary breast tumors shrink with a course of neoadjuvant chemotherapy. Neoadjuvant therapy can reduce the size of large operable breast cancers, permitting breast conservation in some patients who would have required mastectomy on the basis of their initial tumor size. [3] [4] [5] This neoadjuvant approach has now been extended to patients already eligible for breast conservation to reduce the primary tumor size, allowing for a smaller lumpectomy and a better cosmetic result.
The degree of primary tumor response to neoadjuvant therapy also provides prognostic information. Long-term survival is consistently higher in the 10% to 25% of patients with a pathological complete response to preoperative therapy. As a result, the rate of pathological complete response has become a useful early readout for assessing the efficacy of new systemic therapy agents in clinical trials.
In summary, in its present form, neoadjuvant therapy can reduce the extent of surgery required for operable breast cancers, with no decrease in overall survival. Neoadjuvant therapy may also be used to test new treatment regimens and may provide favorable prognostic information for patients who have a pathological complete response.
However, there has been concern that these benefits of neoadjuvant therapy may come at the cost of higher rates of in-breast local recurrence after a lumpectomy. In the NSABP B-18 trial, there was a trend toward higher local recurrence rates after neoadjuvant therapy 4 ; in-breast tumor, recurrence was seen in 10.7% of patients who underwent a lumpectomy after neoadjuvant chemotherapy compared with 7.6% of patients who had a lumpectomy followed by chemotherapy (P = 0.12). Although this difference was not statistically significant, concerns about local recurrence risk have persisted.
There are several plausible models that would explain higher rates of local recurrence after neoadjuvant therapy. Tumors may respond to chemotherapy, leaving scattered islands of tumor within the original tumor bed. Small foci of residual tumors might not be visualized on imaging studies and could be missed with a standard lumpectomy margin assessment. These factors could lead to incomplete tumor excision and increase the risk of local recurrence. In addition, discussion continues about the appropriate extent of a lumpectomy after neoadjuvant therapy. Should the lumpectomy be the size of the original mass or the size of the residual tumor?
In this issue of Annals of Surgery, Mittendorf et al 6 present the largest series to date of breast-conserving therapy after neoadjuvant chemotherapy and find no increase in 5-and 10-year risks of local recurrence with breast conservation. These results extend prior work from their institution. 7 Among 2983 patients who received breastconserving therapy from 1987 to 2005, 652 received neoadjuvant systemic therapy before surgery and 2331 received systemic therapy after surgery. When patients were analyzed by their presenting tumor stage, there was no difference in local-regional recurrence with preoperative versus postoperative systemic therapy. In multivariate analysis, use of neoadjuvant therapy was not associated with an increased risk of local-regional recurrence. Of note, the initial primary tumor T stage was not a significant predictor of local-regional recurrence, confirming that larger tumors downstaged by neoadjuvant therapy may be considered for breast conservation.
These results provide reassurance that patients may enjoy the benefits of neoadjuvant therapy without increasing their risk of local recurrence. They also suggest that early-stage breast cancer patients may be safely included in neoadjuvant therapy trials. The algorithms for breast conservation after neoadjuvant therapy described by Mittendorf et al can be easily applied to most practice settings. Their practice included diagnostic mammography and ultrasonography before and after chemotherapy, with any visible disease included in the lumpectomy target volume. In current practice, breast magnetic resonance imaging could also be used to assess the extent of residual tumor. Lumpectomies were performed excising the tumor volume that remained after neoadjuvant chemotherapy, not the original tumor volume. Surgical margins of 2 mm were deemed sufficient, and reexcisions were performed for margins less than 2 mm. All patients received whole-breast irradiation, with a boost to the tumor bed. Endocrine therapy was used in patients with estrogen receptor-positive tumors.
What do these results tell us about selecting neoadjuvant versus adjuvant systemic therapy for patients with breast cancer? Neoadjuvant therapy remains the standard of care for locally advanced or inoperable breast cancers. For a given patient with operable breast cancer, the order of surgery and chemotherapy will not affect either distant or local recurrence risk. Neoadjuvant therapy may be safely used to reduce the size of the primary tumor to allow for breast conservation or a smaller lumpectomy. Neoadjuvant therapy may be used if it provides access to new therapeutic agents. The neoadjuvant approach may also provide useful prognostic information. These benefits may be obtained without raising concerns about increasing the risk of local recurrence.
Despite the safety of neoadjuvant therapy, there remain groups of patients for whom surgery first, followed by adjuvant systemic therapy, is preferable. In general, the extent of ductal carcinoma in situ is not reduced by neoadjuvant therapy. Invasive lobular carcinomas are unlikely to shrink significantly with neoadjuvant therapy. Breast conservation may be considered when the initial extent of such tumors is reasonably small relative to breast size, and mastectomy may be performed for larger lesions. Neoadjuvant therapy will not improve survival and will not increase the likelihood of breast conservation in these patients.
For patients who will clearly require a mastectomy even after neoadjuvant therapy, such as those with multifocal tumors or invasive cancer with extensive ductal carcinoma in situ, neoadjuvant therapy will provide little, if any, benefit, and may be detrimental if immediate reconstruction is planned. For these patients, surgery first provides detailed nodal staging information, upon which standard postmastectomy radiation therapy algorithms are based. For patients who receive postmastectomy radiation therapy after breast reconstruction, adjuvant chemotherapy provides a greater separation between surgery and radiation therapy. Radiation is delivered 16 to 20 weeks after reconstruction compared with 4 to 8 weeks after reconstruction with the neoadjuvant approach. This additional time for healing of the reconstruction before radiation therapy may help reduce complications. Unless the neoadjuvant approach allows access to some new agent not yet available as adjuvant therapy, it is probably best to perform surgery first.
If ongoing efforts succeed in finding an accurate marker of early primary tumor response to systemic therapy, neoadjuvant therapy may become the preferred approach in a larger portion of breast cancer patients. For now, it remains a useful option that Mittendorf et al show us can be used without compromising local-regional control.
